Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies

Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade

(2020) Yu-Chen Chuang et al.   Frontiers in Immunology

Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses

(2019) Karim Vermaelen   Frontiers in Immunology

Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

(2019) Wylie et al.   Cancers

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization

(2019) Nai-Yun Sun et al.   Cancers

Trends in clinical development for PD-1/PD-L1 inhibitors

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

Special Issue "IFN-Independent ISG Expression and its Role in Antiviral Cell-Intrinsic Innate Immunity"

(2019) Thomas et al.   Viruses-Basel

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

(2019) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade

(2019) Youngmin Jeong et al.   CANCER LETTERS

Soft matter DNA nanoparticles hybridized with CpG motifs and peptide nucleic acids enable immunological treatment of cancer

(2019) Jun-O Jin et al.   JOURNAL OF CONTROLLED RELEASE

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy

(2018) Tsukasa SEYA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

(2018) Maarten Versteven et al.   Frontiers in Immunology

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

(2018) Anastasia Constantinidou et al.   PHARMACOLOGY & THERAPEUTICS

Antigen-presenting cells and T-lymphocytes homing to the thymus shape T cell development

(2018) Jeremy Santamaria et al.   IMMUNOLOGY LETTERS

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

(2018) Wouter W. van Willigen et al.   Frontiers in Immunology

Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues

(2017) D Sichien et al.   Mucosal Immunology

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

(2017) Kelsey A. Gregg et al.   mBio

Lipopolysaccharide-coated CuS nanoparticles promoted anti-cancer and anti-metastatic effect by immuno-photothermal therapy

(2017) Bian Jang et al.   Oncotarget

PD-1/PD-L1 Pathway in Breast Cancer

(2017) Florian Schütz et al.   Oncology Research and Treatment

Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes

(2016) Cherie T. Ng et al.   CELL

PD-1 and its ligands are important immune checkpoints in cancer

(2016) Yinan Dong et al.   Oncotarget

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators

(2016) Signe Tandrup Schmidt et al.   Pharmaceutics

Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate

(2015) Zoltan Beck et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

TLR4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A Differentially Regulate Effector and Memory CD8+ T Cell Differentiation

(2014) W. Cui et al.   JOURNAL OF IMMUNOLOGY

Plasmacytoid, conventional, and monocyte-derived dendritic cells undergo a profound and convergent genetic reprogramming during their maturation

(2013) Thien-Phong Vu Manh et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Adjuvant Activity of Naturally Occurring Monophosphoryl Lipopolysaccharide Preparations from Mucosa-Associated Bacteria

(2013) Paula M. Chilton et al.   INFECTION AND IMMUNITY

Mechanisms of Action of Adjuvants

(2013) Sunita Awate et al.   Frontiers in Immunology

Adjuvants for human vaccines

(2012) Carl R Alving et al.   CURRENT OPINION IN IMMUNOLOGY

Lipopolysaccharide-pretreated plasmacytoid dendritic cells ameliorate experimental chronic kidney disease

(2012) Dong Zheng et al.   KIDNEY INTERNATIONAL

Type 1 Interferons and Antiviral CD8 T-Cell Responses

(2012) Raymond M. Welsh et al.   PLoS Pathogens

CpG DNA as a vaccine adjuvant

(2011) Christian Bode et al.   Expert Review of Vaccines

The Toll-Like Receptor 4 Agonist Monophosphoryl Lipid A Augments Innate Host Resistance to Systemic Bacterial Infection

(2011) Christopher D. Romero et al.   INFECTION AND IMMUNITY

Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors

(2011) H. D. Goold et al.   JOURNAL OF IMMUNOLOGY

Interferon-stimulated genes and their antiviral effector functions

(2011) John W Schoggins et al.   Current Opinion in Virology

Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses

(2010) Xiaopei Huang et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Plasmacytoid Dendritic Cells

(2009) Armin G. Jegalian et al.   ADVANCES IN ANATOMIC PATHOLOGY

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES